Repligen Corporation (RGEN)

Market Cap	6.55B
Revenue (ttm)	673.96M
Net Income (ttm)	-13.83M
Shares Out	56.18M
EPS (ttm)	-0.25
PE Ratio	n/a
Forward PE	60.57
Dividend	n/a
Ex-Dividend Date	n/a

Volume	754,697
Open	118.86
Previous Close	118.91
Day's Range	115.76 - 118.86
52-Week Range	102.97 - 182.52
Beta	1.11
Analysts	Buy
Price Target	169.33 (+45.35%)
Earnings Date	Jul 29, 2025

About RGEN

Repligen Corporation, a life sciences company, develops and commercializes bioprocessing technologies and systems in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products. The company also provides chromatography products, including OPUS pre-packed chromatography columns, which are used in the purification of biologics; and OPUS smaller-scale columns that are used in the high throughput process...

• Industry: Medical Instruments & Supplies
• Sector: Healthcare
• Founded: 1981
• Employees: 1,778
• Stock Exchange: NASDAQ
• Ticker Symbol: RGEN
• Website: https://www.repligen.com

Analyst Summary

According to 11 analysts, the average rating for RGEN stock is "Buy." The 12-month stock price target is $169.33, which is an increase of 45.35% from the latest price.

Price Target

$169.33

(45.35% upside)

Analyst Consensus: Buy